CRISPR GAA Gene Integration for Stable Pompe Disease Expression

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for Pompe disease, such as enzyme replacement therapy and gene replacement therapy with adeno-associated virus vectors, are ineffective in infants due to immune responses and loss of episomal vector genomes, leading to progressive muscle weakness.

Innovation Solution

A gene editing system using CRISPR/Cas9 technology is employed to introduce a repair template for the defective GAA gene, stabilizing GAA expression by creating double-strand breaks and integrating the transgene into cells, particularly in the liver, to produce alpha-glucosidase enzyme.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If adeno-associated virus vectors are used for gene replacement therapy, then GAA expression can be achieved, but episomal vector genomes are lost from the growing liver leading to diminished efficacy

Engineering Contradiction:

ImproveGAA expression stabilityVSAvoidduration of GAA expression

Core Design Contradiction:

ReliabilityVSDuration of action of stationary object

Solution Approach 1:

The CRISPR/Cas9 system performs preliminary action by creating double-strand breaks at specific genomic locations before the transgene integration occurs. This preparatory step enables subsequent homology-directed repair that results in stable genomic integration of the GAA transgene, preventing the loss of expression over time that plagues episomal vector systems.

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The AAV vector serves as an intermediary delivery system that carries both the CRISPR/Cas9 components and the GAA transgene into liver cells. This intermediary approach allows the system to first establish itself in the cell, then use the CRISPR machinery to create permanent genomic integration, combining the delivery advantages of viral vectors with the stability of genomic integration.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If AAV vectors are re-administered to maintain GAA expression, then expression can be sustained, but anti-AAV antibodies are formed rendering re-administration ineffective

Engineering Contradiction:

ImproveGAA expression maintenanceVSAvoidre-administration capability

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The system performs preliminary genomic integration of the GAA transgene through CRISPR-mediated homology-directed repair. This preliminary action creates permanent expression capability that eliminates the need for re-administration, thereby avoiding the anti-AAV antibody problem that prevents repeated dosing.

Inventive Principle:

Principle #10Preliminary action

3Quantity of substance

If enzyme replacement therapy is administered to treat Pompe disease, then GAA activity can be supplemented, but it fails to prevent muscle weakness in infantile-onset patients

Engineering Contradiction:

ImproveGAA enzyme activityVSAvoidclinical efficacy

Core Design Contradiction:

Quantity of substanceVSReliability

Solution Approach 1:

The AAV vector acts as an intermediary delivery vehicle that introduces functional GAA transgene directly into the patient's liver cells. This intermediary approach bypasses the limitations of enzyme replacement therapy by establishing endogenous production of GAA through genomic integration, leading to sustained therapeutic levels of enzyme activity that can prevent muscle weakness when administered early.

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The genomic integration of the GAA transgene enables the patient's own liver cells to produce functional GAA enzyme autonomously. This self-service mechanism eliminates the need for continuous external enzyme supplementation and provides sustained therapeutic effect that can prevent disease progression.

Inventive Principle:

Principle #25Self-service

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The system achieves stable integration and expression of the GAA gene, correcting the underlying defect in Pompe disease, thereby preventing muscle weakness and improving treatment efficacy.